Article
Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Cell cycle (Georgetown, Tex.) - 1 May 2013
Sanhaji Mourad, Louwen Frank, Zimmer Brigitte, Kreis Nina-Naomi, Roth Susanne, Yuan Juping
Abstract excerpt
Polo-like kinase 1 has been established as one of the most attractive targets for molecular cancer therapy. In fact, multiple small-molecule inhibitors targeting this kinase have been developed and intensively investigated. Recently, it has been reported that the cytotoxicity induced by Plk1 inhibition is elevated in cancer cells with inactive p53, leading to the hypothesis that inactive p53 is a predictive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.